Literature DB >> 35386045

Drug-Induced Sexual Dysfunction: An Analysis of Reports to a National Pharmacovigilance Database.

Carolina Valeiro1, Cristiano Matos2, Joep Scholl3, Florence van Hunsel3.   

Abstract

INTRODUCTION: Sexual dysfunction (SD) is a problem that can affect any phase of the sexual response cycle (such as sexual desire, arousal and orgasm) and individuals of any age. SD can be caused by physical reasons, such as medical conditions, alcoholism or drug abuse; psychological factors, such as stress and anxiety; and different medicines, such as selective serotonin reuptake inhibitors (SSRIs), and their associated adverse effects. AIM: The aim of this study was to characterise drugs suspected to have caused SD adverse drug reactions (ADRs) in patients, by conducting a descriptive study based on pharmacovigilance reports.
METHODS: Reports submitted to the Netherlands Pharmacovigilance Centre Lareb from January 2003 to December 2019 were used to investigate drug-induced sexual disorders. Selected reports had at least one ADR reported in the Medical Dictionary for Regulatory Activities (MedDRA®) System Organ Class (SOC) 'Reproductive system and breast disorders' and the SOC 'Psychiatric disorders' relating to sexual disorders and corrected for drug utilisation (expenditure) for the Dutch population.
RESULTS: A total of 2815 SD ADRs were reported in the observed period. Data were divided according to three variables: pharmacotherapeutic group, the drug itself, and sex. A total of 722 different SD/pharmacotherapeutic group pairs were observed. The pharmacotherapeutic groups with the highest frequency of SD reports were SSRIs (n = 488, 17.58%), other antidepressants (n = 172, 6.20%) and HMG-CoA reductase inhibitors (n = 149, 5.37%). Distinguishing ADRs by sex, men suffered more from erectile dysfunction, decreased libido and ejaculation disorders, while among women, libido disorders, dyspareunia and SD were the most common ADRs.
CONCLUSION: Different reactions and disproportionality of reactions were detected between the sexes. Antidepressants, antihypertensives, oral contraceptives, α-blockers, and anti-androgens were the pharmacotherapeutic groups with the highest number of SD reports and corresponding high odds ratios.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35386045     DOI: 10.1007/s40264-022-01174-3

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  53 in total

1.  Female sexual dysfunction in a healthy Austrian cohort: prevalence and risk factors.

Authors:  Anton Ponholzer; Michaela Roehlich; Ursula Racz; Christian Temml; Stephan Madersbacher
Journal:  Eur Urol       Date:  2004-12-02       Impact factor: 20.096

2.  Adverse drug reactions on sexual functioning: a systematic overview.

Authors:  Rineke Gordijn; Martina Teichert; Melianthe P J Nicolai; Henk W Elzevier; Henk-Jan Guchelaar
Journal:  Drug Discov Today       Date:  2019-01-25       Impact factor: 7.851

Review 3.  Female sexual dysfunction: definition, classification, and debates.

Authors:  Ching-Hui Chen; Yen-Chin Lin; Li-Hsuan Chiu; Yuan-Hsiang Chu; Fang-Fu Ruan; Wei-Min Liu; Peng-Hui Wang
Journal:  Taiwan J Obstet Gynecol       Date:  2013-03       Impact factor: 1.705

4.  Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey.

Authors:  Adam Keller Ashton; Brenda D Jamerson; Wendy L Weinstein; Christine Wagoner
Journal:  Curr Ther Res Clin Exp       Date:  2005-03

5.  Sexual Dysfunction in Women: A Practical Approach.

Authors:  Stephanie S Faubion; Jordan E Rullo
Journal:  Am Fam Physician       Date:  2015-08-15       Impact factor: 3.292

6.  Subjective utility ratings of neuroleptics in treating schizophrenia.

Authors:  S E Finn; J M Bailey; R T Schultz; R Faber
Journal:  Psychol Med       Date:  1990-11       Impact factor: 7.723

7.  What is the "true" prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact?

Authors:  Richard D Hayes; Lorraine Dennerstein; Catherine M Bennett; Christopher K Fairley
Journal:  J Sex Med       Date:  2008-02-04       Impact factor: 3.802

8.  FEMALE SEXUAL DYSFUNCTION (FSD) IN WOMEN HEALTH CARE WORKERS.

Authors:  Konstantinos Stamatiou; Maria Margariti; Eftichia Nousi; Dimitra Mistrioti; Richard Lacroix; Maria Saridi
Journal:  Mater Sociomed       Date:  2016-06-01

9.  Epidemiology of Male Sexual Dysfunction in Asian and European Regions: A Systematic Review.

Authors:  Muhammad Irfan; Nik Hazlina Nik Hussain; Norhayati Mohd Noor; Mahaneem Mohamed; Hatta Sidi; Shaiful Bahari Ismail
Journal:  Am J Mens Health       Date:  2020 Jul-Aug

10.  An estimation of patients at potential risk for drug-induced sexual dysfunction using pharmacy dispensing data.

Authors:  Rineke Gordijn; Melianthe P J Nicolai; Henk W Elzevier; Henk-Jan Guchelaar; Martina Teichert
Journal:  Fam Pract       Date:  2021-06-17       Impact factor: 2.267

View more
  1 in total

Review 1.  The Role of the "Anti-Inflammatory" Couple for the Management of Hyperuricemia With Deposition.

Authors:  Andrea Sansone; Yacov Reisman; Suada Meto; Susanna Dolci; Emmanuele A Jannini
Journal:  Sex Med       Date:  2022-09-07       Impact factor: 2.523

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.